Immunome (IMNM) Interest Expenses (2019 - 2026)
Immunome's (IMNM) quarterly Interest Expenses came in at $184.9 million in Q1 2026, up 69943.56% YoY from N/an in Q1 2025, and up 3698200.0% on a QoQ basis from $5000.0 in Q4 2025.
Immunome (IMNM) Interest Expenses (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Interest Expenses data on file, last reported at $184.9 million in Q1 2026.
- Quarterly Interest Expenses rose 69943.56% year-over-year to $184.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $184.9 million (up 25370.39% YoY) and the FY2025 annual result came in at $180.7 million, up 69.29% from the prior year.
- Interest Expenses climbed to $184.9 million in Q1 2026, from $5000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $184.9 million in Q1 2026 to a low of $5000.0 in Q4 2025.
- A 5-year average of $23.0 million and a median of $1.8 million in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2025 — Interest Expenses sank 98.33% — and 2026, when it jumped 69943.56%.
- Tracing IMNM's Interest Expenses over 5 years: stood at $292000.0 in 2022, then tumbled by 78.77% to $62000.0 in 2023, then soared by 383.87% to $300000.0 in 2024, then slumped by 98.33% to $5000.0 in 2025, then surged by 3698200.0% to $184.9 million in 2026.
- The last three Interest Expenses figures came in at $184.9 million (Q1 2026), $5000.0 (Q4 2025), and $41.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 170.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 170.14 Mn |
| Jun 30, 2026 | 170.14 Mn |
| Mar 31, 2026 | 184.92 Mn |
| Mar 31, 2026 | 184.92 Mn |
| Dec 31, 2025 | 5,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | 41.77 Mn |
| Sep 30, 2025 | 41.77 Mn |
| Jun 30, 2025 | 23.83 Mn |
| Jun 30, 2025 | 23.83 Mn |
| Mar 31, 2025 | 264,000.00 |
| Mar 31, 2025 | 264,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 65.61 Mn |
| Sep 30, 2024 | 65.61 Mn |
| Jun 30, 2024 | 46.22 Mn |
| Jun 30, 2024 | 46.22 Mn |
| Mar 31, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |